Month: May 2022

Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the quarter ending March 31, 2022. Product and Pipeline Updates and Other Corporate Developments ZIMHIAccording to the Centers for Disease Control and Prevention (CDC), drug overdoses resulted in over 108,000 deaths in the U.S. over the most recent 12 months of data. Two thirds of these involved fentanyl.Our U.S. commercial partner, US WorldMeds, commercially launched our high dose naloxone product, ZIMHI, at the end of March.We are encouraged by the early acceptance of ZIMHI...

EUGENE, Ore., May 16, 2022 (GLOBE NEWSWIRE) — Arcimoto, Inc.® (NASDAQ: FUV), makers of rightsized, outrageously fun, ultra-efficient electric vehicles for moving people and stuff, today provided a corporate update and announced financial results for the first quarter ended March 31, 2022. Arcimoto will host a stakeholder and analyst webinar today to discuss the company’s results. The webinar will include an investor Q&A powered by Say. To view the webcast, use the links below: First Quarter 2022 Stakeholder WebcastDate: Monday, May 16, 2022Time: 5:00 p.m. ET (2:00 p.m. PDT)Webcast: https://us06web.zoom.us/webinar/register/WN_b7xY14wtTpWJNDkAI538NA First Quarter 2022 and Recent Company HighlightsIn Q1, sold 24 new customer vehicles while shifting manufacturing operations from the AMP to the RAMP. Launched operations at RAMP,...

Company Revenue Increases 31% Sequentially to $13.1 Million in First Quarter of 2022 Second Consecutive Quarter of Margin Improvement Despite Industry-Wide Supply Challenges Company Triples MP Performance Energy Sales in First Quarter of 2022 from Fourth Quarter of 2021 to Over $1.1 Million; Delivers Energy Margins of 35% in First Quarter of 2022 LAS VEGAS, May 16, 2022 (GLOBE NEWSWIRE) — MusclePharm Corporation (“MusclePharm” or the “Company”) (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today reported financial results for the first quarter ended March 31, 2022. Mr. Ryan Drexler, the Chairman of the Board of Directors and Chief Executive Officer, stated, “We delivered sequential revenue improvement in the first quarter of 2022 with revenue of $13.1 million, up from...

PHOENIX, May 16, 2022 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB:MFON), maker of the award-winning Recurrency platform that increases customer engagement through mobile messaging and personalized digital offers, and drives digital transformation for brands, today announced financial results for the first quarter (“Q1”) ending March 31, 2022. First Quarter 2022 Financial HighlightsRevenues of $2.0 million compared to $2.5 million in Q1 2021. The year-over-year decrease in revenue was primarily due to the restructuring of a large customer contract due to COVID related changes in their business. Gross margin of 42.1% compared to 57.6% in Q1 2021. The decrease in gross margin was primarily due to the restructuring of the aforementioned large customer contract. Net loss was $1.9 million compared to $1.7 million in Q1 2021. Cash...

– $130 Million in Non-Dilutive Capital Strengthened Financial Position – – Presentations at Upcoming ASGCT Annual Meeting Include First-Time Details of Mechanism of Action of Nuclease-Free Gene Editing Candidate HMI-103 for PKU; Symposium to Feature Lead Principal Investigator for the pheEDIT Trial – – Additional Presentations on GTx-mAb Platform and Characterization of Proprietary AAVHSC Capsid with Low Liver Tropism – – Submitted Response to FDA with Information Requested for pheNIX Gene Therapy Trial Clinical Hold – BEDFORD, Mass., May 16, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2022, and highlighted recent accomplishments. “During the first quarter of 2022,...

— Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April — — Announced initiation and dosing of first patient in Phase 2 Trial of IOB102-IOB103 in combination with KEYTRUDA® (pembrolizumab) as first line treatment in multi-arm basket trial — — Strong Balance Sheet with ~$188 million Cash Runway to Support Multiple Data readouts into mid-2024 — NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today financial results for the quarter ended March 31, 2022. “During our first quarter and in recent weeks we continued to advance our promising...

SAN JOSE, Calif., May 16, 2022 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (NASDAQ: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the first quarter ended March 31, 2022. As of March 31, 2022, the Fund’s net assets were approximately $87.4 million, or $12.68 per share, compared with net assets of approximately $94.8 million, or $13.75 per share as of December 31, 2021. As of March 31, 2022, the Fund’s portfolio included public and private securities valued at approximately $82.2 million, or $11.93 per share, which includes approximately $0.01 per share in cash and cash equivalents. Portfolio Summary (as of 3/31/22)Investment Fair Value1,   Fair Valueper Share1,2Equity/Debt Investments $82.19 million   $11.92Cash/Cash...